Floatz logo

Loncastuximab Tesirine

Central Nervous System Lymphoma

University of Utahantibody_drug_conjugatePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

73 Active assets in the Central Nervous System Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
(+)-VINCRISTINE
Ono Pharmaceutical Co., Ltd.
Phase 4BBB
METHOTREXATE
Assistance Publique Hopitaux De Marseille
Phase 4BB
Orelabrutinib
The First Affiliated Hospital with Nanjing Medical University
Phase 3BB
Idarubicine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB

View all 50 →

Same molecule, other indications

Loncastuximab Tesirine is also rated in:

Refractory Diffuse Large B-Cell LymphomaDormant
B
Indicative ·
62 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
B
Indicative ·
61 / 100
View asset →
Refractory B-Cell Non-Hodgkin LymphomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →